Recent Updates
Recently added Catalysts

PRX-105

Phase 1

Organophosphate Exposure | Small molecule | Other |Protalix BioTherapeutics, Inc. (DE)|Last Updated: Sep 4, 2012

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
UNCONTROLLED
Total Trials1
Total Enrollment10
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT01093859An Exploratory Phase 1 Microdose Study of PRX-105EARLY_PHASE1 COMPLETED 10Mar 1, 2010Aug 1, 2010Sep 4, 2012 -
Unlock Drug Trial Details
Study Design & Arms
Interventions
NameTypeDescription
PRX-105DRUGSterile solution for intravenous injection
Unlock Study Design Details